{{Rsnum
|rsid=10825264
|Gene=PCDH15
|Chromosome=10
|position=55947954
|Orientation=plus
|GMAF=0.365
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 4.7 | 23.4 | 71.9
| HCB | 77.8 | 17.8 | 4.4
| JPT | 86.7 | 11.1 | 2.2
| YRI | 7.9 | 28.6 | 63.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 77.8 | 17.8 | 4.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10825264
|Name_s=
|Gene_s=PCDH15
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109443
}}

{{PMID|17701890|OA=1
}} Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10825264
|overall_frequency_n=36
|overall_frequency_d=124
|overall_frequency=0.290323
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}